These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35078498)

  • 1. Exosome-liposome hybrid nanoparticle codelivery of TP and miR497 conspicuously overcomes chemoresistant ovarian cancer.
    Li L; He D; Guo Q; Zhang Z; Ru D; Wang L; Gong K; Liu F; Duan Y; Li H
    J Nanobiotechnology; 2022 Jan; 20(1):50. PubMed ID: 35078498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
    Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
    Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
    Yin S; Mai Z; Liu C; Xu L; Xia C
    Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Triptolide-Loaded Exosomes on the Proliferation and Apoptosis of Human Ovarian Cancer SKOV3 Cells.
    Liu H; Shen M; Zhao D; Ru D; Duan Y; Ding C; Li H
    Biomed Res Int; 2019; 2019():2595801. PubMed ID: 31240207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
    Ma J; Liu L; Ling Y; Zheng J
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative regulation of PI3K/AKT/mTOR axis regulates fibroblast proliferation, apoptosis and autophagy play a vital role in triptolide-induced epidural fibrosis reduction.
    Dai J; Sun Y; Chen D; Zhang Y; Yan L; Li X; Wang J
    Eur J Pharmacol; 2019 Dec; 864():172724. PubMed ID: 31600493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein tyrosine phosphatase receptor type Z1 inhibits the cisplatin resistance of ovarian cancer by regulating PI3K/AKT/mTOR signal pathway.
    Wang P; Hu Y; Qu P; Zhao Y; Liu J; Zhao J; Kong B
    Bioengineered; 2022 Jan; 13(1):1931-1941. PubMed ID: 35001804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF β1 promotes the polarization of M2-type macrophages and activates PI3K/mTOR signaling pathway by inhibiting ISG20 to sensitize ovarian cancer to cisplatin.
    Wu J; Jiang L; Wang S; Peng L; Zhang R; Liu Z
    Int Immunopharmacol; 2024 Jun; 134():112235. PubMed ID: 38761779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of REG4 expression on chemoresistance of ovarian cancer.
    Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
    J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin‑resistant SKOV3/DDP ovarian cancer cells.
    Zhong Y; Le F; Cheng J; Luo C; Zhang X; Wu X; Xu F; Zuo Q; Tan B
    Oncol Rep; 2021 May; 45(5):. PubMed ID: 33760192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
    Wang H; Li Y; Wang Y; Shang X; Yan Z; Li S; Bao W
    J Gynecol Oncol; 2024 Mar; 35(2):e13. PubMed ID: 37921598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Exosome-Mediated Delivery of Triptolide Endowed with Targeting Properties as Chemotherapy Carriers for Ovarian Carcinoma.
    He D; Xu X; Li L; Chen C; Gong K; Guo Q; Liu F; Wang Y; Duan Y; Li H
    J Biomed Nanotechnol; 2021 Mar; 17(3):426-438. PubMed ID: 33875077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-Delivery of Triptolide and Curcumin for Ovarian Cancer Targeting Therapy via mPEG-DPPE/CaP Nanoparticle.
    Liu L; Xiong X; Shen M; Ru D; Gao P; Zhang X; Huang C; Sun Y; Li H; Duan Y
    J Biomed Nanotechnol; 2018 Oct; 14(10):1761-1772. PubMed ID: 30041722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA‑22 mediates the cisplatin resistance of osteosarcoma cells by inhibiting autophagy via the PI3K/Akt/mTOR pathway.
    Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Xue HQ; Sun L; Sun C; Feng W; Guo SB
    Oncol Rep; 2020 Apr; 43(4):1169-1186. PubMed ID: 32323781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamine metabolism targeting liposomes for synergistic chemosensitization and starvation therapy in ovarian cancer.
    Cai X; Shi S; Chen G; Zhong M; Yang Y; Mai Z; Tian Y; Tan J; He L; Cui C; Yu Z; Wang X
    Acta Biomater; 2023 Mar; 158():560-570. PubMed ID: 36596434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
    Ma N; Zhao Y
    Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
    Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.